Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Stage III/IV Extranodal NK-T-Cell Lymphoma

NCT02544425 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02544425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02544425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Stage III/IV Extranodal NK-T-Cell Lymphoma
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
February 21, 2016
Completion date
November 30, 2021
Enrollment
27 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal nk-t-cell lymphoma